Insight Molecular Diagnostics (IMDX)
Develops molecular diagnostic tests for transplant rejection and oncology therapy programs.
Something off on this page? Send us feedback.
Focuses molecular diagnostic work on testing for transplanted-organ rejection while retaining intellectual-property programs for oncology therapy selection and therapy monitoring. Its portfolio spans laboratory-developed tests, research-use-only kits, and in-vitro-diagnostic kitted clinical tests.
Centers its operating focus on molecular testing for transplanted-organ rejection after a pivot from the wider OncoCyte portfolio. A name change and move to Nashville accompanied that refocus. The rebranded company retains intellectual-property programs for oncology therapy selection and therapy monitoring alongside its organ-transplant work.
Uses laboratory-developed tests, research-use-only kits, and in-vitro-diagnostic kitted clinical tests. Its principal executive office and CLIA-certified laboratory are in Nashville; it stated that it expects to retain a laboratory and R&D center in Göttingen, Germany. The portfolio is organized around organ transplant, oncology therapy selection, and oncology therapy monitoring.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Feb 17, 2026 | Lake Street | Reiterate | Rating: —Target: $0.50 | Target: $12 |
| Nov 11, 2025 | Needham | Reiterate | Rating: —Target: $4.25 | Target: $9 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $17.8M · Total debt $2.6M · Total assets $29.4M · Shareholders' equity −$21.3M
- Revenue
- $239.0K
- Operating income
- −$11.4M
- Net income
- −$11.3M
No dividends on record.
| Institutions | 56.42% | 18.46M shares | |
|---|---|---|---|
| 41 holders · as of Jun 30, 2026 | |||
| Insiders | 11.54% | 3.78M shares | |
| 7 holders · as of Jul 6, 2026 | |||
| Strategic holders | 123.08% | 40.28M shares | |
| 2 holders · as of Apr 27, 2026 | |||
| Adds to | 191.04% | ||
32.72M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 191.04%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Broadwood Partners, L.P.1Strategic10 percent owner | 114.64% | 37.51M | filed Apr 27, 2026 |
Broadwood Capital IncInstitution | 38.76% | 12.68M | as of Jun 30, 2026 |
Patrick W. SmithInsider10 percent owner | 9.96% | 3.26M | filed Feb 11, 2025 |
Awm Investment Company, Inc.Institution | 8.67% | 2.84M | as of Jun 30, 2026 |
Bio-Rad Laboratories, IncStrategic | 8.45% | 2.76M | filed Mar 4, 2025 |
- Broadwood Partners, L.P. reports a block also reported by Broadwood Capital Inc; it is counted once, under Broadwood Capital Inc.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 23, 2026 | Broadwood Partners, L.P. | 10 percent owner | +280,381 | $3.50 |
| Apr 24, 2026 | Broadwood Partners, L.P. | 10 percent owner | +38,880 | $3.53 |
| Apr 27, 2026 | Broadwood Partners, L.P. | 10 percent owner | +250,923 | $3.64 |
| Apr 16, 2026 | Broadwood Partners, L.P. | 10 percent owner | +102,057 | $3.45 |
| Apr 17, 2026 | Broadwood Partners, L.P. | 10 percent owner | +40,114 | $3.57 |
